TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

PRISM

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: US

Quick snapshot

PRISM

ST13

US500000088985145

Class

42

Filing

88985145

Registration

7374715

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

Attention: there is active risk

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

66

Latest update

04/30/2024

Classification

Registered

Trademark type

Word

Nice classes

42

Filing date

01/25/2019

Registration date

04/30/2024

Expiration date

-

Recommended action

Perform a full collision analysis and validate classes before any filing or trademark investment.

Next step

These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.

Complete case details

Structured fields from the responsible authority and the official record.

Status date

04/30/2024

Last transaction

04/30/2024

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Filing basis

Intent to use

First use anywhere

01/27/2023

First use in commerce

09/23/2023

Drawing code

4

Owner type

99

Owner location

Singapore, SG

Examiner

MMEJE, OBIEZE GINIKANWA

Law office

N40

Current location

PUBLICATION AND ISSUE SECTION

Holders and representatives

Holders

Wave Life Sciences Ltd.

Representatives

Sara Bauer Womble Bond Dickinson (US) LLP

Technical classification

Nice Classes

Class 42

Vienna Codes

No Vienna codes available.

Goods and services

Class 42

Research and development of oligonucleotide drug delivery platforms for use in the treatment of genetic diseases and disorders; research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of genetic diseases and disorders; research and development of oligonucleotide compounds for targeted gene silencing

Publications

History of USPTO decisions and trademark events.

66 publications found

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

04/30/2024

R.PR

REGISTERED-PRINCIPAL REGISTER

04/30/2024

SUNA

NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

03/26/2024

CNPR

ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED

03/24/2024

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

02/15/2024

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

02/15/2024

ALIE

ASSIGNED TO LIE

02/15/2024

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

09/26/2023

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

07/10/2023

GNRT

NON-FINAL ACTION E-MAILED

07/10/2023

CNRT

SU - NON-FINAL ACTION - WRITTEN

07/10/2023

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

06/07/2023

SUPC

STATEMENT OF USE PROCESSING COMPLETE

06/06/2023

DPCC

DIVISIONAL PROCESSING COMPLETE

06/06/2023

EX3G

SOU EXTENSION 3 GRANTED

06/06/2023

AITU

CASE ASSIGNED TO INTENT TO USE PARALEGAL

05/30/2023

IUAF

USE AMENDMENT FILED

05/08/2023

DRRR

DIVISIONAL REQUEST RECEIVED

05/08/2023

EXT3

SOU EXTENSION 3 FILED

05/08/2023

ERTD

TEAS REQUEST TO DIVIDE RECEIVED

05/08/2023

EEXT

SOU TEAS EXTENSION RECEIVED

05/08/2023

EISU

TEAS STATEMENT OF USE RECEIVED

05/08/2023

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

04/12/2023

ECDR

TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS

04/12/2023

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

04/12/2023

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

04/12/2023

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

10/08/2022

EX2G

SOU EXTENSION 2 GRANTED

10/06/2022

EXT2

SOU EXTENSION 2 FILED

10/06/2022

EEXT

SOU TEAS EXTENSION RECEIVED

10/06/2022

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

04/26/2022

EX1G

SOU EXTENSION 1 GRANTED

04/22/2022

EXT1

SOU EXTENSION 1 FILED

04/22/2022

EEXT

SOU TEAS EXTENSION RECEIVED

04/22/2022

NOAM

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

11/09/2021

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

09/14/2021

PUBO

PUBLISHED FOR OPPOSITION

09/14/2021

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

08/26/2021

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

08/09/2021

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

07/08/2021

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

07/08/2021

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

07/08/2021

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

03/08/2021

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

03/08/2021

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

03/08/2021

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

03/08/2021

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

03/08/2021

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

01/11/2021

GNRT

NON-FINAL ACTION E-MAILED

01/11/2021

CNRT

NON-FINAL ACTION WRITTEN

01/11/2021

GNS3

NOTIFICATION OF LETTER OF SUSPENSION E-MAILED

06/07/2020

GNSL

LETTER OF SUSPENSION E-MAILED

06/07/2020

CNSL

SUSPENSION LETTER WRITTEN

06/07/2020

ALIE

ASSIGNED TO LIE

06/04/2020

GNS3

NOTIFICATION OF LETTER OF SUSPENSION E-MAILED

11/16/2019

GNSL

LETTER OF SUSPENSION E-MAILED

11/16/2019

CNSL

SUSPENSION LETTER WRITTEN

11/16/2019

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

10/12/2019

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

10/11/2019

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

10/11/2019

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

04/13/2019

GNRT

NON-FINAL ACTION E-MAILED

04/13/2019

CNRT

NON-FINAL ACTION WRITTEN

04/13/2019

DOCK

ASSIGNED TO EXAMINER

04/08/2019

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

02/19/2019

NWAP

NEW APPLICATION ENTERED

01/29/2019

Continuous trademark protection

Get notified about every new filing that threatens PRISM or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.